Trial reportThe Journal of clinical endocrinology and metabolism2009
Transdermal nitroglycerin therapy may not prevent early postmenopausal bone loss.
Trial report in The Journal of clinical endocrinology and metabolism, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01387672 (Nitrates and Bone Turnover), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Nitrates and Bone Turnover (NABT): Trial to Select the Best Nitrate Preparation
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- The Efficacy of Nitrates for Bone Health: A Systematic Review and Meta-Analysis of Observational and Randomized Controlled Studies.Frontiers in endocrinology · 2022Pooled it
- The effects of organic nitrates on osteoporosis: a systematic review.Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2013Pooled it
- Nitric oxide modulates bone anabolism through regulation of osteoblast glycolysis and differentiation.The Journal of clinical investigation · 2021Trial
- Trial
- The Role of Endothelial Dysfunction in Fracture Healing: Mechanisms and Potential Effects on Skeletal Repair.International journal of molecular sciences · 2026Review
- The potential role of nitrate, a nitric oxide donor, in the prevention and treatment of diabetic osteoporosis.Frontiers in endocrinology · 2025Review
- Protein kinase G2 activation restores Wnt signaling and bone mass in glucocorticoid-induced osteoporosis in mice.JCI insight · 2024Article
- A plasma membrane-associated form of the androgen receptor enhances nuclear androgen signaling in osteoblasts and prostate cancer cells.Science signaling · 2024Article
- Protein Kinase G2 Is Essential for Skeletal Homeostasis and Adaptation to Mechanical Loading in Male but Not Female Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2023Article
- Long-term inorganic nitrate administration protects against ovariectomy-induced osteoporosis in rats.EXCLI journal · 2022Article
- Nitric oxide and bone: The phoenix rises again.The Journal of clinical investigation · 2021Article
- Nitric oxide and cyclic GMP functions in bone.Nitric oxide : biology and chemistry · 2018Review
- Increasing dietary nitrate has no effect on cancellous bone loss or fecal microbiome in ovariectomized rats.Molecular nutrition & food research · 2017Article
- Intermittent Nitrate Use and Risk of Hip Fracture.The American journal of medicine · 2017Article
- A Novel, Direct NO Donor Regulates Osteoblast and Osteoclast Functions and Increases Bone Mass in Ovariectomized Mice.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2017Article
- Nitrate Medications, Fractures, and Change in Bone Mineral Density in Postmenopausal Women: Results from the Women's Health Initiative.Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research · 2016Observational
- Soluble guanylate cyclase as a novel treatment target for osteoporosis.Endocrinology · 2014Article
- Organic nitrate metabolism and action: toward a unifying hypothesis and the future-a dedication to Professor Leslie Z. Benet.Journal of pharmaceutical sciences · 2013Review
- Organic nitrates for osteoporosis: an update.BoneKEy reports · 2013Article
- Local delivery of nitric oxide: targeted delivery of therapeutics to bone and connective tissues.Advanced drug delivery reviews · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
contextOsteoporosis is common among postmenopausal women; animal studies and human pilot studies support the concept of nitric oxide (NO) donors reducing bone mineral density loss.
objectiveThe objective of the study was to evaluate whether NO donor, nitroglycerin, prevents postmenopausal bone loss.
designThis was a 3-yr randomized, double blinded, single-center, placebo-controlled clinical trial.
settingThe single-center study was conducted at the University of Medicine and Dentistry-Robert Wood Johnson Medical School (New Brunswick, NJ).
participantsParticipants included 186 postmenopausal women aged 40-65 yr, with lumbar bone mineral density (BMD) T-scores of 0 to -2.5.
interventionWomen, stratified by lumbar T-score (<-1.50 and >or=-1.50) and years since menopause (<or=5 and >5 yr), were randomized to receive nitroglycerin ointment (22.5 mg as Nitro-Bid) or placebo ointment received daily for 3 yr. Both groups took 630 mg daily calcium plus 400 IU vitamin D supplements. MEASUREMENTS: BMD was measured at 6 months and annually by dual-energy x-ray absorptiometry. Percent change in lumbar vertebrae BMD was the primary outcome. Hip BMD, total body bone mineral content, and height were secondary outcomes.
resultsAfter 36 months of therapy, changes of -2.1% in the active group (n = 88) and -2.5% in the placebo group (n = 82) in lumbar spine BMD were seen (P = 0.59; 95% confidence interval -1.001, 1.975). Secondary outcomes also did not differ by intervention arm. The active group reported more headaches compared with the placebo group (57 vs. 14%, P < 0.001). Other adverse and serious adverse events were not different.
conclusionsBMD changes did not substantially differ between postmenopausal women who received the dose of nitroglycerin tested, in comparison with a placebo. Once-daily dosing with 22.5 mg of transdermal-administered nitroglycerin was not effective (compliance adjusted dose was only approximately 16 mg/d); a sub-therapeutic dose.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.